Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Sharp + Dohme Corp.

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

Msd Italia S.r.l.

Merck + Co., Inc.

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.

Istituto Di Ricerche Di Biologia Molecolare P. Angletti Spa

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Frank Narjes

Joerg Habermann

Ian Stansfield

Uwe Koch

Cristina Gardelli

Simona Ponzi

Nigel J Liverton

Anandan Palani

Hao Wu

Peng Li

Casey Cameron McComas

Xing Dai

Shuwen He

Michael Rowley

Hong Liu

Richard Soll

Xuanjia Peng

Steven Harper

Jesus Maria Ontoria Ontoria

Immacolata Conte

Stefania Colarusso

Maria Del Rosario Rico Ferreira

Philippe L Durette

Qun Dang

Nicolas Zorn

Marco Poma

Zhong Lai

Barbara Pacini

Monica Donghi

Barbara Attenni

Caterina Ercolani

Malte Meppen

Malcolm MacCoss

Ravi P Nargund

Dong Xiao

David Brian Olsen

Vincenzo Summa

Alessia Petrocchi

Clare London

Ester Muraglia

Konrad Koehler

Victor Giulio Matassa

Savina Malancona

Claudio Giuliano

Jose Ignacio Martin Hernando

Marco Pompei

Vicenzo Summa

Antonella Marchetti

Jesus Ontoria

Victor Matassa

Benjamin Gerlach

Angela Mackay

Elena Capito

Casey Cameron Mccomas

Nicholas Zorn

Qung Dang

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases

Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases

The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R, R, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Pentacyclic indole derivatives as antiviral agents

The present invention provides nucleoside cyclic phosphoramidates of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection using the compounds of formula (I). 

Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection

Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and Rare as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed. 

Antiviral indoles

The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention. (I) 

Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection

A class of macrocyclic compounds of formula (I), wherein R, A, Ar, B, D, F, M, Q, Q, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. 

Therapeutic compounds

The present invention relates to tetracyclic thienopyrrole compounds of formula (I), wherein Ar, A, D1, D2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Thienopyrroles as antiviral agents

The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention. 

The present invention relates to indole compounds of the formula (I): wherein R, R, R, R, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections. 

Indole derivatives as antiviral agents

The present invention relates to tetracyclic indole compounds of formula (I): wherein R, R, A, Ar, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

Tetracyclic indole derivatives as antiviral agents

Compounds of the formula (I): wherein A, B, D, M, Ar, W, X, Y, Z and Rare as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

The present invention relates to thienopyrrole compounds of formula (I); wherein A, B, Y, Ar, n, Z and Xare as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections. 

Growing community of inventors

Rome, Italy

Frank Narjes